| P/E (FY) | — | Sales (TTM) | SEK 257.4M |
| Earnings (TTM) | -SEK 177.1M | ROE | −18.24% |
| Net Margin | −68.81% | ROIC | −44.19% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 112.85% |
BioArctic AB is a Swedish company that researches and develops biological drugs, particularly antibodies, for patients with central nervous system disorders that carry high unmet medical needs. Its therapeutic focus includes neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease, and its portfolio centers on Lecanemab in intravenous and subcutaneous forms, alongside additional candidates such as Exidavnemab and several preclinical and research-stage programs. The company has a research and collaboration agreement with Eli Lilly combining its BrainTransporter technology with a Lilly molecule. Formerly named BioArctic Neuroscience AB, it took its current name in 2016, was incorporated in 2000, and is based in Stockholm, Sweden.
| Market Cap | $2.93B | Trading Days | 2153 |
| 52W High | 364.40 |
| 52W Low | 204.60 |
| % Off High | −11.47% |
| YTD | 4.41% | 1Y | 49.82% |
| 3Y | 10.30% | 5Y | 128.21% |
| Since incept. (ann.) | 31.92% |
| Ann. Volatility (1Y) | 47.81% | Ann. Volatility (3Y) | 60.26% |
| Sharpe (1Y) | 1.10 | Sharpe (3Y) | 0.37 |
| Max Drawdown (1Y) | −22.49% | Max Drawdown (3Y) | −57.61% |
| Beta (3Y, vs SPY) | 1.27 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CLDX | Celldex Therapeutics, Inc. | $2.94B | — |
| WRBY | Warby Parker Inc. | $2.95B | 2603.0 |
| XRAY | DENTSPLY SIRONA Inc. | $2.84B | — |
| BLLN | BillionToOne, Inc. | $2.84B | 380.6 |
| PRVA | Privia Health Group, Inc. | $3.04B | 134.0 |
| IRON | Disc Medicine, Inc. | $2.81B | — |
| MBX | MBX Biosciences, Inc. | $3.04B | — |
| 028300.KQ | Hlb Inc | $2.77B | — |
| IDYA | IDEAYA Biosciences, Inc. | $3.13B | — |
| GRAL | GRAIL, Inc. | $2.72B | — |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $2.71B | — |
| SUPN |
| SUPERNUS PHARMACEUTICALS, INC. |
| $2.70B |
| — |
